Selected research
Industry Research
Hospital Injectable Drugs Industry Research Report 2026
Market perspective
The global Hospital Injectable Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Hospital Injectable Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Hospital Injectable Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Hospital Injectable Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Hospital Injectable Drugs include Hospira (Pfizer Inc.), Baxter, Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent) and Teva Pharmaceutical, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Hospital Injectable Drugs market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Hospital Injectable Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hospital Injectable Drugs Market by Company
Hospira (Pfizer Inc.)
Baxter
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Otsuka
B.Braun
JW Life Science
Auromedics
Sanofi
Gland Pharma
Endo International PLC
Sichuan Kelun Pharmaceutical
Cisen Pharmaceutical
Shijiazhuang No. 4 Pharmaceutical
Shandong Hualu Pharmaceutical
CR Double-Crane
Hospital Injectable Drugs Segment by Type
Generic Sterile Injectables
Sterile Intravenous (IV) Solutions
Hospital Injectable Drugs Segment by Application
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases
Hospital Injectable Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hospital Injectable Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hospital Injectable Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hospital Injectable Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Hospital Injectable Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Generic Sterile Injectables
- Sterile Intravenous (IV) Solutions
Applications
- Oncology
- Anesthesia
- Anti-Infectives
- Parenteral Nutrition
- Cardiovascular Diseases
Companies covered
- Hospira (Pfizer Inc.)
- Baxter
- Fresenius Kabi
- Sandoz (Novartis)
- Hikma Pharmaceuticals PLC
- Dr. Reddy’s Laboratories Ltd
- Grifols
- Nichi-Iko Group (Sagent)
- Teva Pharmaceutical
- Otsuka
- B.Braun
- JW Life Science
- Auromedics
- Sanofi
- Gland Pharma
- Endo International PLC
- Sichuan Kelun Pharmaceutical
- Cisen Pharmaceutical
- Shijiazhuang No. 4 Pharmaceutical
- Shandong Hualu Pharmaceutical
- CR Double-Crane
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Hospital Injectable Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Generic Sterile Injectables
- 2.2.3 Sterile Intravenous (IV) Solutions
- 2.3 Hospital Injectable Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Oncology
- 2.3.3 Anesthesia
- 2.3.4 Anti-Infectives
- 2.3.5 Parenteral Nutrition
- 2.3.6 Cardiovascular Diseases
- 2.4 Assumptions and Limitations
3 Hospital Injectable Drugs Breakdown Data by Type
- 3.1 Global Hospital Injectable Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Hospital Injectable Drugs Forecasted Market Size by Type (2027-2032)
4 Hospital Injectable Drugs Breakdown Data by Application
- 4.1 Global Hospital Injectable Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Hospital Injectable Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Hospital Injectable Drugs Market Perspective (2021-2032)
- 5.2 Global Hospital Injectable Drugs Growth Trends by Region
- 5.2.1 Global Hospital Injectable Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Hospital Injectable Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Hospital Injectable Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Hospital Injectable Drugs Market Dynamics
- 5.3.1 Hospital Injectable Drugs Industry Trends
- 5.3.2 Hospital Injectable Drugs Market Drivers
- 5.3.3 Hospital Injectable Drugs Market Challenges
- 5.3.4 Hospital Injectable Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Hospital Injectable Drugs Players by Revenue
- 6.1.1 Global Top Hospital Injectable Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Hospital Injectable Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Hospital Injectable Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Hospital Injectable Drugs Head Office and Area Served
- 6.4 Global Hospital Injectable Drugs Players, Product Type & Application
- 6.5 Global Hospital Injectable Drugs Manufacturers Established Date
- 6.6 Global Hospital Injectable Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Hospital Injectable Drugs Market Size (2021-2032)
- 7.2 North America Hospital Injectable Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Hospital Injectable Drugs Market Size by Country (2021-2026)
- 7.4 North America Hospital Injectable Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Hospital Injectable Drugs Market Size (2021-2032)
- 8.2 Europe Hospital Injectable Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Hospital Injectable Drugs Market Size by Country (2021-2026)
- 8.4 Europe Hospital Injectable Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Hospital Injectable Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Hospital Injectable Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Hospital Injectable Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Hospital Injectable Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Hospital Injectable Drugs Market Size (2021-2032)
- 10.2 South America Hospital Injectable Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Hospital Injectable Drugs Market Size by Country (2021-2026)
- 10.4 South America Hospital Injectable Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Hospital Injectable Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Hospital Injectable Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Hospital Injectable Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Hospital Injectable Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Hospira (Pfizer Inc.)
- 12.1.1 Hospira (Pfizer Inc.) Company Information
- 12.1.2 Hospira (Pfizer Inc.) Business Overview
- 12.1.3 Hospira (Pfizer Inc.) Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.1.4 Hospira (Pfizer Inc.) Hospital Injectable Drugs Product Portfolio
- 12.1.5 Hospira (Pfizer Inc.) Recent Developments
- 12.2 Baxter
- 12.2.1 Baxter Company Information
- 12.2.2 Baxter Business Overview
- 12.2.3 Baxter Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.2.4 Baxter Hospital Injectable Drugs Product Portfolio
- 12.2.5 Baxter Recent Developments
- 12.3 Fresenius Kabi
- 12.3.1 Fresenius Kabi Company Information
- 12.3.2 Fresenius Kabi Business Overview
- 12.3.3 Fresenius Kabi Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.3.4 Fresenius Kabi Hospital Injectable Drugs Product Portfolio
- 12.3.5 Fresenius Kabi Recent Developments
- 12.4 Sandoz (Novartis)
- 12.4.1 Sandoz (Novartis) Company Information
- 12.4.2 Sandoz (Novartis) Business Overview
- 12.4.3 Sandoz (Novartis) Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.4.4 Sandoz (Novartis) Hospital Injectable Drugs Product Portfolio
- 12.4.5 Sandoz (Novartis) Recent Developments
- 12.5 Hikma Pharmaceuticals PLC
- 12.5.1 Hikma Pharmaceuticals PLC Company Information
- 12.5.2 Hikma Pharmaceuticals PLC Business Overview
- 12.5.3 Hikma Pharmaceuticals PLC Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.5.4 Hikma Pharmaceuticals PLC Hospital Injectable Drugs Product Portfolio
- 12.5.5 Hikma Pharmaceuticals PLC Recent Developments
- 12.6 Dr. Reddy’s Laboratories Ltd
- 12.6.1 Dr. Reddy’s Laboratories Ltd Company Information
- 12.6.2 Dr. Reddy’s Laboratories Ltd Business Overview
- 12.6.3 Dr. Reddy’s Laboratories Ltd Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.6.4 Dr. Reddy’s Laboratories Ltd Hospital Injectable Drugs Product Portfolio
- 12.6.5 Dr. Reddy’s Laboratories Ltd Recent Developments
- 12.7 Grifols
- 12.7.1 Grifols Company Information
- 12.7.2 Grifols Business Overview
- 12.7.3 Grifols Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.7.4 Grifols Hospital Injectable Drugs Product Portfolio
- 12.7.5 Grifols Recent Developments
- 12.8 Nichi-Iko Group (Sagent)
- 12.8.1 Nichi-Iko Group (Sagent) Company Information
- 12.8.2 Nichi-Iko Group (Sagent) Business Overview
- 12.8.3 Nichi-Iko Group (Sagent) Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.8.4 Nichi-Iko Group (Sagent) Hospital Injectable Drugs Product Portfolio
- 12.8.5 Nichi-Iko Group (Sagent) Recent Developments
- 12.9 Teva Pharmaceutical
- 12.9.1 Teva Pharmaceutical Company Information
- 12.9.2 Teva Pharmaceutical Business Overview
- 12.9.3 Teva Pharmaceutical Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.9.4 Teva Pharmaceutical Hospital Injectable Drugs Product Portfolio
- 12.9.5 Teva Pharmaceutical Recent Developments
- 12.10 Otsuka
- 12.10.1 Otsuka Company Information
- 12.10.2 Otsuka Business Overview
- 12.10.3 Otsuka Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.10.4 Otsuka Hospital Injectable Drugs Product Portfolio
- 12.10.5 Otsuka Recent Developments
- 12.11 B.Braun
- 12.11.1 B.Braun Company Information
- 12.11.2 B.Braun Business Overview
- 12.11.3 B.Braun Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.11.4 B.Braun Hospital Injectable Drugs Product Portfolio
- 12.11.5 B.Braun Recent Developments
- 12.12 JW Life Science
- 12.12.1 JW Life Science Company Information
- 12.12.2 JW Life Science Business Overview
- 12.12.3 JW Life Science Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.12.4 JW Life Science Hospital Injectable Drugs Product Portfolio
- 12.12.5 JW Life Science Recent Developments
- 12.13 Auromedics
- 12.13.1 Auromedics Company Information
- 12.13.2 Auromedics Business Overview
- 12.13.3 Auromedics Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.13.4 Auromedics Hospital Injectable Drugs Product Portfolio
- 12.13.5 Auromedics Recent Developments
- 12.14 Sanofi
- 12.14.1 Sanofi Company Information
- 12.14.2 Sanofi Business Overview
- 12.14.3 Sanofi Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.14.4 Sanofi Hospital Injectable Drugs Product Portfolio
- 12.14.5 Sanofi Recent Developments
- 12.15 Gland Pharma
- 12.15.1 Gland Pharma Company Information
- 12.15.2 Gland Pharma Business Overview
- 12.15.3 Gland Pharma Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.15.4 Gland Pharma Hospital Injectable Drugs Product Portfolio
- 12.15.5 Gland Pharma Recent Developments
- 12.16 Endo International PLC
- 12.16.1 Endo International PLC Company Information
- 12.16.2 Endo International PLC Business Overview
- 12.16.3 Endo International PLC Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.16.4 Endo International PLC Hospital Injectable Drugs Product Portfolio
- 12.16.5 Endo International PLC Recent Developments
- 12.17 Sichuan Kelun Pharmaceutical
- 12.17.1 Sichuan Kelun Pharmaceutical Company Information
- 12.17.2 Sichuan Kelun Pharmaceutical Business Overview
- 12.17.3 Sichuan Kelun Pharmaceutical Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.17.4 Sichuan Kelun Pharmaceutical Hospital Injectable Drugs Product Portfolio
- 12.17.5 Sichuan Kelun Pharmaceutical Recent Developments
- 12.18 Cisen Pharmaceutical
- 12.18.1 Cisen Pharmaceutical Company Information
- 12.18.2 Cisen Pharmaceutical Business Overview
- 12.18.3 Cisen Pharmaceutical Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.18.4 Cisen Pharmaceutical Hospital Injectable Drugs Product Portfolio
- 12.18.5 Cisen Pharmaceutical Recent Developments
- 12.19 Shijiazhuang No. 4 Pharmaceutical
- 12.19.1 Shijiazhuang No. 4 Pharmaceutical Company Information
- 12.19.2 Shijiazhuang No. 4 Pharmaceutical Business Overview
- 12.19.3 Shijiazhuang No. 4 Pharmaceutical Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.19.4 Shijiazhuang No. 4 Pharmaceutical Hospital Injectable Drugs Product Portfolio
- 12.19.5 Shijiazhuang No. 4 Pharmaceutical Recent Developments
- 12.20 Shandong Hualu Pharmaceutical
- 12.20.1 Shandong Hualu Pharmaceutical Company Information
- 12.20.2 Shandong Hualu Pharmaceutical Business Overview
- 12.20.3 Shandong Hualu Pharmaceutical Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.20.4 Shandong Hualu Pharmaceutical Hospital Injectable Drugs Product Portfolio
- 12.20.5 Shandong Hualu Pharmaceutical Recent Developments
- 12.21 CR Double-Crane
- 12.21.1 CR Double-Crane Company Information
- 12.21.2 CR Double-Crane Business Overview
- 12.21.3 CR Double-Crane Revenue in Hospital Injectable Drugs Business (2021-2026)
- 12.21.4 CR Double-Crane Hospital Injectable Drugs Product Portfolio
- 12.21.5 CR Double-Crane Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst